Sanofi ADR

AI Summary

Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].

Sanofi is a major French pharmaceutical company with $104.3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10.1 billion in free cash flow and a 5.55% dividend yield [Yahoo Finance].

Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].

Recent News

• Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

  Yahoo Finance· 2026-05-18

• Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

  Yahoo Finance· 2026-05-18

• A Look At Sanofi (ENXTPA:SAN) Valuation After Recent Share Price Weakness

  Simply Wall St· 2026-05-18

• Sanofi Deepens AI And Alzheimer’s Research While Shares Trade Below Targets

  Simply Wall St· 2026-05-18

• Sanofi: Information concerning the total number of voting rights and shares - April 2026

  Yahoo Finance· 2026-05-19